20273 results for «»
20273 results
Luisa Salido
Madrid, Spain
Andrea Santarelli
Rimini, Italy
Diogo Ferreira
Vila Nova de Gaia, Portugal
Roberto Scacciavillani
Rome, Italy
FAME 3: A Randomized Trial of FFR-Guided Stenting Compared With CABG
12 Nov 2021
Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability of the FAME 3 trial presented at TCT 2021.
Patita Sitticharoenchai
New York, United States of America
Paola Spatuzza
San Giovanni Rotondo, Italy
Jayakumar Sreenivasan
New York, United States of America
FAVOR III China: Angiographic quantitative flow ratio-guided coronary intervention - a multicentre, randomised, sham-controlled trial
04 Nov 2021
Nicola Ryan provides her take on this investigator initiated, multicentre, randomised, blinded, sham controlled trial compares clinical outcomes of QFR versus angiography guided strategies for the treatment of non-critical lesions in patients with stable or unstable angina or MI at least 72 hours prior to screening....
Author
Juan Manuel Telayna
Buenos Aires Province, Argentina
Evelina Toscano
Monza, Italy
SUGAR: A Randomized Trial of Amphilimus-eluting Stents and Zotarolimus-eluting Stents in Patients With Diabetes
04 Nov 2021
TCT 2021: Luis Ortega Paz interviews Rafael Romaguera, principal investigator of the SUGAR trial. SUGAR is the first powered trial to compare new generation DES in patients with diabetes, and also the first to include a broad population of patients with diabetes (all-comers design). It was...
Author
Author
Antoine Vaillier
Marseille, France
Frittitta Valentina
Catania, Italy
Roberto Valvo
MILANO, Italy
Ciro Vella
Milan, Italy
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
Mathilde Vely
Rennes, France
Silvio Humberto Vera Vera
Hospital Universitario la Paz, Spain
Zuyue Wang
Plano, United States of America
